Melenor (Risedronate Sodium)

Risedronate sodium binds to hydroxyapatite on bone surfaces and is taken up by osteoclasts during resorption. This binding inhibits the mevalonate pathway, leading to reduced osteoclast activity and apoptosis, which shifts bone remodeling toward net bone formation.

The specific dose of Melenor is determined by the prescribing clinician based on the patient’s diagnosis, renal function, and other clinical factors. The prescriber will select the appropriate strength and dosing schedule in accordance with approved labeling and local guidelines.

Safety of risedronate sodium in pregnancy and lactation has not been established. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Melenor product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other bisphosphonates such as alendronate, risedronate offers similar efficacy in increasing bone mineral density but may be administered weekly rather than daily, which can improve adherence. It differs from newer agents like denosumab, a subcutaneous monoclonal antibody, in both route of administration and mechanism of action.

Store Melenor at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Do not store in areas of high humidity or near heat sources, and keep the container tightly closed when not in use.

Melenor is taken orally, usually with a full glass of plain water on an empty stomach. Patients should remain upright for at least 30 minutes after ingestion and avoid eating, drinking, or taking other medications during this period to ensure optimal absorption.

The most serious adverse events linked to risedronate include osteonecrosis of the jaw, atypical femoral fractures, severe esophagitis, and acute hypersensitivity reactions. Patients should promptly report persistent jaw pain, unusual thigh or groin pain, or signs of severe allergic response to their healthcare provider.

Melenor is contraindicated in patients with known hypersensitivity to risedronate or other bisphosphonates, those with severe renal impairment (creatinine clearance <30 mL/min), and individuals unable to remain upright for 30 minutes after dosing. It should also be avoided in patients with esophageal disorders that delay emptying.